Merck & Co. at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Merck & Co. brings 3 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2639. Merck supports a symposium on polycythemia vera and myeloproliferative neoplasm care. Its research covers the LSD1 inhibitor bomedemstat for sickle cell disease and fatigue measures in essential thrombocythemia.
| Organization | ASH 2026 Attendance |
|---|---|
Merck & Co. Rahway, NJ | |
Global pharmaceutical company, known as MSD outside the US and Canada, with a broad oncology clinical research program spanning many tumor types. | Booth Exhibiting at Booth 2639 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 7:00pm–10:00pm From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients Treatment options for polycythemia vera and essential thrombocythemia after first-line therapy fails, including new targeted drugs for patients with unmet needs. Poster Sat Dec 12 5:30pm–7:30pm Poster Sun Dec 13 6:00pm–8:00pm |
Find decision makers at Merck & Co.
Tell us what you sell and we’ll find the people at Merck & Co. most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction